Effect on CD4 T-cell count of replacing protease inhibitors in patients with successful HIV suppression

A meta-analysis

Carolyn Owen, Farouk Kazim, Andrew David Badley

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Protease inhibitor (PI) therapy may be associated with adverse events. Switching the PI component to a non-PI may reduce some side-effects, but the immune effects are unclear. In a meta-analysis using strict inclusion criteria, a randomized switch from PI was associated with impaired CD4 T-cell gains compared with maintaining PI (PI arm +32 cells, effect size 0.130, P = 0.05). Therefore, PI-based therapy results in superior CD4 T-cell gains compared with switching to a non-PI regimen.

Original languageEnglish (US)
Pages (from-to)693-695
Number of pages3
JournalAIDS
Volume18
Issue number4
DOIs
StatePublished - Mar 5 2004

Fingerprint

CD4 Lymphocyte Count
Protease Inhibitors
Meta-Analysis
HIV
T-Lymphocytes
Cell Size
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Effect on CD4 T-cell count of replacing protease inhibitors in patients with successful HIV suppression : A meta-analysis. / Owen, Carolyn; Kazim, Farouk; Badley, Andrew David.

In: AIDS, Vol. 18, No. 4, 05.03.2004, p. 693-695.

Research output: Contribution to journalArticle

@article{a97025603f9c4b54908eb093c81eb2d5,
title = "Effect on CD4 T-cell count of replacing protease inhibitors in patients with successful HIV suppression: A meta-analysis",
abstract = "Protease inhibitor (PI) therapy may be associated with adverse events. Switching the PI component to a non-PI may reduce some side-effects, but the immune effects are unclear. In a meta-analysis using strict inclusion criteria, a randomized switch from PI was associated with impaired CD4 T-cell gains compared with maintaining PI (PI arm +32 cells, effect size 0.130, P = 0.05). Therefore, PI-based therapy results in superior CD4 T-cell gains compared with switching to a non-PI regimen.",
author = "Carolyn Owen and Farouk Kazim and Badley, {Andrew David}",
year = "2004",
month = "3",
day = "5",
doi = "10.1097/00002030-200403050-00016",
language = "English (US)",
volume = "18",
pages = "693--695",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Effect on CD4 T-cell count of replacing protease inhibitors in patients with successful HIV suppression

T2 - A meta-analysis

AU - Owen, Carolyn

AU - Kazim, Farouk

AU - Badley, Andrew David

PY - 2004/3/5

Y1 - 2004/3/5

N2 - Protease inhibitor (PI) therapy may be associated with adverse events. Switching the PI component to a non-PI may reduce some side-effects, but the immune effects are unclear. In a meta-analysis using strict inclusion criteria, a randomized switch from PI was associated with impaired CD4 T-cell gains compared with maintaining PI (PI arm +32 cells, effect size 0.130, P = 0.05). Therefore, PI-based therapy results in superior CD4 T-cell gains compared with switching to a non-PI regimen.

AB - Protease inhibitor (PI) therapy may be associated with adverse events. Switching the PI component to a non-PI may reduce some side-effects, but the immune effects are unclear. In a meta-analysis using strict inclusion criteria, a randomized switch from PI was associated with impaired CD4 T-cell gains compared with maintaining PI (PI arm +32 cells, effect size 0.130, P = 0.05). Therefore, PI-based therapy results in superior CD4 T-cell gains compared with switching to a non-PI regimen.

UR - http://www.scopus.com/inward/record.url?scp=1642361231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642361231&partnerID=8YFLogxK

U2 - 10.1097/00002030-200403050-00016

DO - 10.1097/00002030-200403050-00016

M3 - Article

VL - 18

SP - 693

EP - 695

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 4

ER -